Literature DB >> 10974578

Susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to cefditoren, and provisional interpretive criteria.

P C Fuchs1, A L Barry, S D Brown.   

Abstract

In vitro cefditoren antimicrobial activity was tested by broth microdilution and disk diffusion methods against 300 Streptococcus pneumoniae and 299 Haemophilus influenzae isolates. MICs were also determined for three comparison drugs. The MICs of cefditoren were very comparable to those of cefotaxime against both species. If penicillin-resistant pneumococci are to be considered not susceptible to cefditoren, the tentative MIC breakpoints for cefditoren of < or = 0.25 microg/ml for susceptible and > or 1.0 microg/ml for resistant could be selected. With these breakpoints, all penicillin-susceptible pneumococci were cefditoren-susceptible, as were 85% of penicillin-intermediate strains. Provisional zone diameter breakpoints would be > or = 26 mm for susceptible and < or = 20 mm for resistant. If penicillin-resistant pneumococcal infections are shown to clinically respond to cefditoren therapy, then a susceptible MIC breakpoint of < or = 1.0 microg/ml would be appropriate, with a corresponding zone diameter breakpoint of > or = 21 mm. A susceptible MIC breakpoint of < or = 0.5 or < or = 1.0 microg/ml is appropriate for H. influenzae, but lack of correlation between cefditoren MICs and disk diffusion zone diameters when testing H. influenzae leads us to make no recommendations at this time regarding cefditoren disk tests for H. influenzae.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10974578     DOI: 10.1016/s0732-8893(00)00160-7

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  4 in total

1.  Antimicrobial surveillance of Haemophilus influenzae in the United States during 2000-2001 leads to detection of clonal dissemination of a beta-lactamase-negative and ampicillin-resistant strain.

Authors:  James A Karlowsky; Ian A Critchley; Renée S Blosser-Middleton; Elena A Karginova; Mark E Jones; Clyde Thornsberry; Daniel F Sahm
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

Review 2.  Cefditoren pivoxil: a review of its use in the treatment of bacterial infections.

Authors:  Keri Wellington; Monique P Curran
Journal:  Drugs       Date:  2004       Impact factor: 9.546

3.  Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid.

Authors:  Thomas P Lodise; Martina Kinzig-Schippers; George L Drusano; Ulrich Loos; Friedrich Vogel; Jürgen Bulitta; Markus Hinder; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

Review 4.  Cefditoren pivoxil.

Authors:  Malcolm J M Darkes; Greg L Plosker
Journal:  Drugs       Date:  2002       Impact factor: 11.431

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.